Current indications of secondary enucleation in retinoblastoma management: A position paper on behalf of the european retinoblastoma group (EURbG)

Autores
Stathopoulos, Christina; Lumbroso Le Rouic, Livia; Moll, Annette C.; Parulekar, Manoj; Maeder, Philippe; Doz, François; Jenkinson, Helen; Popovic, Maja Beck; Chantada, Guillermo Luis; Munier, Francis L.
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Secondary enucleation (SE) puts an irreversible end to eye-preserving therapies, whenever their prolongation is expected to violate the presumed state of metastatic grace. At present, it must be acknowledged that clear criteria for SE are missing, leading to empiric and subjective indications commonly related to disease progression or relapse, disease persistence masking the optic nerve head or treatment-related complications obscuring the fundus view. This absence of evidence-based consensus regarding SE is explained by the continuously moving frontiers of the conservative management as a result of diagnostic and therapeutic advances, as well as by the lack of studies sufficiently powered to accurately stratify the risk of metastasis in conservatively treated patients. In this position paper of the European Retinoblastoma Group (EURbG), we give an overview of the progressive shift in the indications for SE over the past decades and propose guidelines to assist decision-making with respect to when SE becomes imperative or recommended, with corresponding absolute and relative SE indications. Further studies and validation of biologic markers correlated with the risk of metastasis are expected to set more precisely the frontiers of conservative management and thus consensual criteria for SE in the future.
Fil: Stathopoulos, Christina. Universite de Lausanne; Suiza
Fil: Lumbroso Le Rouic, Livia. Institut Curie; Francia
Fil: Moll, Annette C.. Vrije Universiteit Amsterdam; Países Bajos
Fil: Parulekar, Manoj. Birmingham Children's Hospital; Reino Unido
Fil: Maeder, Philippe. Centre Hospitalier Universitaire Vaudois; Suiza
Fil: Doz, François. Université de Paris; Francia
Fil: Jenkinson, Helen. Birmingham Women’s and Children’s NHS Foundation Trust; Reino Unido
Fil: Popovic, Maja Beck. Centre Hospitalier Universitaire Vaudois; Suiza
Fil: Chantada, Guillermo Luis. Hospital Sant Joan de Deu Barcelona; España. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Munier, Francis L.. Universite de Lausanne; Suiza
Materia
EXTERNAL BEAM IRRADIATION
INTRA-ARTERIAL CHEMOTHERAPY
INTRAVENOUS CHEMOTHERAPY
METASTASIS
RETINOBLASTOMA
SECONDARY ENUCLEATION
SURVIVAL
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/184217
Acceder
id CONICETDig_f1068c4358c867d39bdf7a80e32bb8b9
oai_identifier_str oai:ri.conicet.gov.ar:11336/184217
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Current indications of secondary enucleation in retinoblastoma management: A position paper on behalf of the european retinoblastoma group (EURbG)Stathopoulos, ChristinaLumbroso Le Rouic, LiviaMoll, Annette C.Parulekar, ManojMaeder, PhilippeDoz, FrançoisJenkinson, HelenPopovic, Maja BeckChantada, Guillermo LuisMunier, Francis L.EXTERNAL BEAM IRRADIATIONINTRA-ARTERIAL CHEMOTHERAPYINTRAVENOUS CHEMOTHERAPYMETASTASISRETINOBLASTOMASECONDARY ENUCLEATIONSURVIVALhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Secondary enucleation (SE) puts an irreversible end to eye-preserving therapies, whenever their prolongation is expected to violate the presumed state of metastatic grace. At present, it must be acknowledged that clear criteria for SE are missing, leading to empiric and subjective indications commonly related to disease progression or relapse, disease persistence masking the optic nerve head or treatment-related complications obscuring the fundus view. This absence of evidence-based consensus regarding SE is explained by the continuously moving frontiers of the conservative management as a result of diagnostic and therapeutic advances, as well as by the lack of studies sufficiently powered to accurately stratify the risk of metastasis in conservatively treated patients. In this position paper of the European Retinoblastoma Group (EURbG), we give an overview of the progressive shift in the indications for SE over the past decades and propose guidelines to assist decision-making with respect to when SE becomes imperative or recommended, with corresponding absolute and relative SE indications. Further studies and validation of biologic markers correlated with the risk of metastasis are expected to set more precisely the frontiers of conservative management and thus consensual criteria for SE in the future.Fil: Stathopoulos, Christina. Universite de Lausanne; SuizaFil: Lumbroso Le Rouic, Livia. Institut Curie; FranciaFil: Moll, Annette C.. Vrije Universiteit Amsterdam; Países BajosFil: Parulekar, Manoj. Birmingham Children's Hospital; Reino UnidoFil: Maeder, Philippe. Centre Hospitalier Universitaire Vaudois; SuizaFil: Doz, François. Université de Paris; FranciaFil: Jenkinson, Helen. Birmingham Women’s and Children’s NHS Foundation Trust; Reino UnidoFil: Popovic, Maja Beck. Centre Hospitalier Universitaire Vaudois; SuizaFil: Chantada, Guillermo Luis. Hospital Sant Joan de Deu Barcelona; España. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Munier, Francis L.. Universite de Lausanne; SuizaMultidisciplinary Digital Publishing Institute2021-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/184217Stathopoulos, Christina; Lumbroso Le Rouic, Livia; Moll, Annette C.; Parulekar, Manoj; Maeder, Philippe; et al.; Current indications of secondary enucleation in retinoblastoma management: A position paper on behalf of the european retinoblastoma group (EURbG); Multidisciplinary Digital Publishing Institute; Cancers; 13; 14; 7-2021; 1-182072-6694CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3390/cancers13143392info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2072-6694/13/14/3392info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:57:44Zoai:ri.conicet.gov.ar:11336/184217instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:57:44.764CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Current indications of secondary enucleation in retinoblastoma management: A position paper on behalf of the european retinoblastoma group (EURbG)
title Current indications of secondary enucleation in retinoblastoma management: A position paper on behalf of the european retinoblastoma group (EURbG)
spellingShingle Current indications of secondary enucleation in retinoblastoma management: A position paper on behalf of the european retinoblastoma group (EURbG)
Stathopoulos, Christina
EXTERNAL BEAM IRRADIATION
INTRA-ARTERIAL CHEMOTHERAPY
INTRAVENOUS CHEMOTHERAPY
METASTASIS
RETINOBLASTOMA
SECONDARY ENUCLEATION
SURVIVAL
title_short Current indications of secondary enucleation in retinoblastoma management: A position paper on behalf of the european retinoblastoma group (EURbG)
title_full Current indications of secondary enucleation in retinoblastoma management: A position paper on behalf of the european retinoblastoma group (EURbG)
title_fullStr Current indications of secondary enucleation in retinoblastoma management: A position paper on behalf of the european retinoblastoma group (EURbG)
title_full_unstemmed Current indications of secondary enucleation in retinoblastoma management: A position paper on behalf of the european retinoblastoma group (EURbG)
title_sort Current indications of secondary enucleation in retinoblastoma management: A position paper on behalf of the european retinoblastoma group (EURbG)
dc.creator.none.fl_str_mv Stathopoulos, Christina
Lumbroso Le Rouic, Livia
Moll, Annette C.
Parulekar, Manoj
Maeder, Philippe
Doz, François
Jenkinson, Helen
Popovic, Maja Beck
Chantada, Guillermo Luis
Munier, Francis L.
author Stathopoulos, Christina
author_facet Stathopoulos, Christina
Lumbroso Le Rouic, Livia
Moll, Annette C.
Parulekar, Manoj
Maeder, Philippe
Doz, François
Jenkinson, Helen
Popovic, Maja Beck
Chantada, Guillermo Luis
Munier, Francis L.
author_role author
author2 Lumbroso Le Rouic, Livia
Moll, Annette C.
Parulekar, Manoj
Maeder, Philippe
Doz, François
Jenkinson, Helen
Popovic, Maja Beck
Chantada, Guillermo Luis
Munier, Francis L.
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv EXTERNAL BEAM IRRADIATION
INTRA-ARTERIAL CHEMOTHERAPY
INTRAVENOUS CHEMOTHERAPY
METASTASIS
RETINOBLASTOMA
SECONDARY ENUCLEATION
SURVIVAL
topic EXTERNAL BEAM IRRADIATION
INTRA-ARTERIAL CHEMOTHERAPY
INTRAVENOUS CHEMOTHERAPY
METASTASIS
RETINOBLASTOMA
SECONDARY ENUCLEATION
SURVIVAL
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Secondary enucleation (SE) puts an irreversible end to eye-preserving therapies, whenever their prolongation is expected to violate the presumed state of metastatic grace. At present, it must be acknowledged that clear criteria for SE are missing, leading to empiric and subjective indications commonly related to disease progression or relapse, disease persistence masking the optic nerve head or treatment-related complications obscuring the fundus view. This absence of evidence-based consensus regarding SE is explained by the continuously moving frontiers of the conservative management as a result of diagnostic and therapeutic advances, as well as by the lack of studies sufficiently powered to accurately stratify the risk of metastasis in conservatively treated patients. In this position paper of the European Retinoblastoma Group (EURbG), we give an overview of the progressive shift in the indications for SE over the past decades and propose guidelines to assist decision-making with respect to when SE becomes imperative or recommended, with corresponding absolute and relative SE indications. Further studies and validation of biologic markers correlated with the risk of metastasis are expected to set more precisely the frontiers of conservative management and thus consensual criteria for SE in the future.
Fil: Stathopoulos, Christina. Universite de Lausanne; Suiza
Fil: Lumbroso Le Rouic, Livia. Institut Curie; Francia
Fil: Moll, Annette C.. Vrije Universiteit Amsterdam; Países Bajos
Fil: Parulekar, Manoj. Birmingham Children's Hospital; Reino Unido
Fil: Maeder, Philippe. Centre Hospitalier Universitaire Vaudois; Suiza
Fil: Doz, François. Université de Paris; Francia
Fil: Jenkinson, Helen. Birmingham Women’s and Children’s NHS Foundation Trust; Reino Unido
Fil: Popovic, Maja Beck. Centre Hospitalier Universitaire Vaudois; Suiza
Fil: Chantada, Guillermo Luis. Hospital Sant Joan de Deu Barcelona; España. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Munier, Francis L.. Universite de Lausanne; Suiza
description Secondary enucleation (SE) puts an irreversible end to eye-preserving therapies, whenever their prolongation is expected to violate the presumed state of metastatic grace. At present, it must be acknowledged that clear criteria for SE are missing, leading to empiric and subjective indications commonly related to disease progression or relapse, disease persistence masking the optic nerve head or treatment-related complications obscuring the fundus view. This absence of evidence-based consensus regarding SE is explained by the continuously moving frontiers of the conservative management as a result of diagnostic and therapeutic advances, as well as by the lack of studies sufficiently powered to accurately stratify the risk of metastasis in conservatively treated patients. In this position paper of the European Retinoblastoma Group (EURbG), we give an overview of the progressive shift in the indications for SE over the past decades and propose guidelines to assist decision-making with respect to when SE becomes imperative or recommended, with corresponding absolute and relative SE indications. Further studies and validation of biologic markers correlated with the risk of metastasis are expected to set more precisely the frontiers of conservative management and thus consensual criteria for SE in the future.
publishDate 2021
dc.date.none.fl_str_mv 2021-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/184217
Stathopoulos, Christina; Lumbroso Le Rouic, Livia; Moll, Annette C.; Parulekar, Manoj; Maeder, Philippe; et al.; Current indications of secondary enucleation in retinoblastoma management: A position paper on behalf of the european retinoblastoma group (EURbG); Multidisciplinary Digital Publishing Institute; Cancers; 13; 14; 7-2021; 1-18
2072-6694
CONICET Digital
CONICET
url http://hdl.handle.net/11336/184217
identifier_str_mv Stathopoulos, Christina; Lumbroso Le Rouic, Livia; Moll, Annette C.; Parulekar, Manoj; Maeder, Philippe; et al.; Current indications of secondary enucleation in retinoblastoma management: A position paper on behalf of the european retinoblastoma group (EURbG); Multidisciplinary Digital Publishing Institute; Cancers; 13; 14; 7-2021; 1-18
2072-6694
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers13143392
info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2072-6694/13/14/3392
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269481418620928
score 13.13397

Publicaciones similares